1. Adis Insight 2016 Adis Insight http://adisinsight.springer.com/drugs/800009809
2. Phase 1, single center, open-label study to determine the cerebrospinal fluid (CSF) levels of NS1209 following an intravenous bolus/2- or 4-hours infusion of NS1209 in patients with epilepsy. NS1209-003. Neurosearch report. 2008 quoted in: Gormsen L, Finnerup NB, Almqvist PM, Jensen TS. 2009 The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study;Ben-Menachem;Anesth Analg,2008
3. Behavioural effects of the novel AMPA/GluR5 selective receptor antagonist NS1209 after systemic administration in animal models of experimental pain;Blackburn-Munro;Neuropharmacol,2004
4. Translational research: crossing the valley of death;Butler;Nature,2008
5. Intracerebral injection of AMPA causes axonal damage in vivo;Fowler;Brain Res,2003